Celldex Therapeutics Inc (CLDX) USD0.001

Sell:$22.01Buy:$28.33$0.50 (2.11%)

Prices delayed by at least 15 minutes
Sell:$22.01
Buy:$28.33
Change:$0.50 (2.11%)
Deal now
Prices delayed by at least 15 minutes
Sell:$22.01
Buy:$28.33
Change:$0.50 (2.11%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Key people

Anthony S. Marucci
President, Chief Executive Officer, Director
Sam Martin
Chief Financial Office, Senior Vice President, Secretary
Tibor Keler
Executive Vice President, Chief Scientific Officer
Freddy A. Jimenez
Senior Vice President, General Counsel
Sarah Cavanaugh
Senior Vice President - Corporate Affairs and Administration
Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Margo Heath-Chiozzi
Senior Vice President - Regulatory Affairs
Ronald A. Pepin
Senior Vice President and Chief Business Officer
Richard Wright
Senior Vice President, Chief Commercial Officer
Diane C. Young
Senior Vice President, Chief Medical Officer
Karen Lipton Shoos
Independent Chairman of the Board
Keith L. Brownlie
Independent Director
Cheryl L. Cohen
Independent Director
Herbert J. Conrad
Independent Director
Rita I. Jain
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US15117B2025
  • Market cap
    $1.57bn
  • Employees
    160
  • Shares in issue
    66.34m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.